Cancer Immunotherapy Global Market to Realize Healthy 5.7% CAGR

June 27, 2017

Wellesley, Mass., Jun 27, 2017 – New monoclonal antibodies, therapeutic cancer vaccines, adoptive cell therapies, and other novel immunotherapeutic technologies have brought a stream of product approvals to the global cancer immunotherapy market in recent years. In 2016, the market expanded by more than 10% from the previous year, reaching $73 billion, a figure which should grow to $95.6 billion by 2021 on a 5.6% CAGR, according to Cancer Immunology and Oncolytic Virology: Technologies and Global Markets.

The new BCC Research report predicts that during the next decade checkpoint inhibitors and of single and combined therapies for various types of cancers will surge into the market. Tecentriq, a PD-1L–targeting antibody, gained a long-awaited approval in June 2016 for the treatment of locally advanced or metastatic urothelial cancer (a type of bladder cancer) and subsequently for the treatment of metastatic NSCLC in October 2016. Yervoy, the first checkpoint inhibitor in the market, is already being pressured by new generations of PD-1 and PD-1L inhibitors. Novel checkpoint inhibitors also await regulatory filing as second-line treatment for various types of cancer.

The market for checkpoint-inhibitor drugs will exhibit a 19.4% CAGR, the highest growth rate among immunotherapy products, the study reports. Immunomodulators are anticipated to achieve the second-highest growth rate with an estimated 8.4% CAGR.  Growth of other therapeutic antibodies is expected to remain relatively constant through 2021 due to several patent expiries, pressure from anticipated generic entries, and newly introduced classes of drugs expected by 2021.

Research Highlights

  • The combined sales from both segments are expected to make up for nearly one-third of the market, with a combined sales value of $28 billion in 2021.
  • Japan will grow at a 9.6% CAGR, nearly twice the growth rate of the rest of the regional markets.
  • T-VEC (talimogene laherparepvec) by Amgen is the only approved oncolytic virus in the major pharmaceutical markets while in China, the first oncolytic virus therapy received approval in 2005

"In 2016, with $38.8 billion, U.S. regional sales contributed more than 53% of the sales generated in the global market," says Robert G Hunter, Senior Editor Healthcare, BCC Research. "The U.S. is expected to remain the global leader among the regional markets with a sustained market share, while Europe is expected to remain in second place with total accrued sales of $20.5 billion in 2021."

Editors and reporters who wish to speak with the analyst should contact Steven Cumming at

Cancer Immunology and Oncolytic Virology: Technologies and Global Markets( PHM129B )
Publish Date: May 2017    

Data and analysis extracted from this press release must be accompanied by a statement identifying BCC Research LLC as the source and publisher. For media inquiries, email or visit to request access to our library of market research.